Indonesia Liver Diseases Therapeutics Market Report 2022 to 2030

Indonesia Liver Diseases Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Indonesia Liver Disease Therapeutics market will reach a value of $216 Mn from $139 Mn in 2022, growing at a CAGR of 5.7% during 2022-2030. Liver Disease Therapeutics in Indonesia are dominated by a few domestic pharmaceutical companies such as Kalbe Farma, Dexa Medica, and Combiphar. The Liver Disease Therapeutics market in Indonesia is segmented into different types of disease and different therapy types. Some of the major factors affecting the Indonesia Liver Disease Therapeutics market are the growing prevalence of liver diseases and unhealthy and dynamic lifestyles.

ID: IN10IDPH040 CATEGORY: Pharmaceuticals GEOGRAPHY: Indonesia AUTHOR: Dr. Vishwa Modhia

Buy Now

Indonesia Liver Disease Therapeutics Analysis Summary

By 2030, it is anticipated that the Indonesia Liver Disease Therapeutics market will reach a value of $216 Mn from $139 Mn in 2022, growing at a CAGR of 5.7% during 2022-2030.

Indonesia is a lower middle-income, developing country located in Southeastern Asia between the Indonesian Ocean and the Pacific Ocean. In recent years, the Indonesian government has undertaken steps to enhance access to liver disease treatment, notably for viral hepatitis. Antiviral medicines for hepatitis B and C are available in Indonesia, and the government has taken steps to minimise treatment costs and promote access to these therapies for individuals in need.

According to the latest WHO data published in 2020 Liver Disease Deaths in Indonesia reached 89,583 or 5.30% of total deaths. The age-adjusted Death Rate is 40.20 per 100,000 of population ranks Indonesia 25^th in the world. Indonesia's government spent 3.4% of its GDP on healthcare in 2020.

Indonesia Liver Disease Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

Non-alcoholic fatty liver disease (NAFLD) is becoming more prevalent in Indonesia, particularly among those who are obese or have type 2 diabetes. NAFLD is predicted to impact approximately 25% of the adult population in Indonesia. Patients with chronic liver illness in Indonesia may also be eligible for specialised care through the National Referral Hospital for Hepatobiliary Disease, which offers diagnostic tests, specialist consultations, and liver transplant services. Low labour costs and a demographic dividend provide a competitive advantage while doing business in Indonesia. Business Process Outsourcing (BPO) in Indonesia is increasing. These aspects could boost Indonesia's Liver Disease Therapeutics market.

Market Restraints

Some people in Indonesia still utilise traditional Indonesian medicine to treat liver diseases, such as Jammu and traditional Javanese medicine. Alcohol-related liver illness is extremely common in Indonesia, particularly among people who abuse alcohol. According to a 2018 study, 42 % of patients with liver cirrhosis had a history of alcohol consumption. Despite the government's efforts in healthcare, financing for specific research programmes remains constrained. This can make it challenging to get the necessary funds for research and development of new liver cancer treatments. Indonesia is vulnerable to changes in Chinese demand, as well as continuous corruption and a lack of openness. These factors may deter new entrants into the Indonesia Liver Disease Therapeutics market.

Competitive Landscape

Key Players

PT Kalbe Farma: PT Kalbe Farma is an Indonesian pharmaceutical company that produces a range of therapeutic products, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Essentiale Forte N
PT Dexa Medica: PT Dexa Medica is an Indonesian pharmaceutical company that produces a variety of therapeutics, including those for liver disease. Its liver disease products include Ursodeoxycholic acid and Silymarin
PT Combiphar: PT Combiphar is an Indonesian pharmaceutical company that produces a range of therapeutic products, including those for liver disease
PT Indofarma: PT Indofarma is an Indonesian pharmaceutical company that produces a variety of therapeutics, including those for liver disease

Recent Notable Updates

December 2022: Kalbe announced that Kalbe has finalised Share Purchase Agreement among Sanofi Aventis Participations, Hoechst GmbH, dan PT Usaha Minidin Raya, collectively referred to as Sellers, with Kalbe and its subsidiary as the Buyers. With the completion of the Share Purchase Agreement requirements, PT Kalbe Farma has effectively acquired 100 % control of PT Aventis Pharma.

Healthcare Policies and Reimbursement Scenarios

In Indonesia, the regulation and reimbursement of liver therapeutics are primarily overseen by the National Agency of Drug and Food Control (NADFC) and the National Health Insurance (JKN) system, respectively. In terms of reimbursement, the JKN system covers the cost of liver therapeutics for eligible patients.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Disease Therapeutics Segmentation

By Treatment Type (Revenue, USD Billion):

Chemotherapy
Antiviral Drugs
Vaccines
Immunosuppressants
Corticosteroids
Immunoglobulins
Targeted Therapy

By Disease Type (Revenue, USD Billion):

Non-alcoholic Fatty Liver Disease (NAFLD)
Autoimmune Diseases
Cancer
Hepatitis
Genetic Disorder
Others

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.